TGF-beta receptor superfamily and related kinases

The target group 'MINK, ALK6, ACVR2B and related kinases' refers to a cluster of serine/threonine kinases primarily involved in the transforming growth factor-beta (TGF-beta) and bone morphogenetic protein (BMP) signaling pathways (Yingling et al., 2017). This group includes Misshapen-like kinase 1 (MINK1), Activin receptor-like kinase 6 (ALK6, also known as BMPR1B), and Activin receptor type-2B (ACVR2B) (MedChemExpress). These proteins play critical roles in regulating cell growth, differentiation, apoptosis, and the epithelial-mesenchymal transition (EMT), which are vital for normal development and tissue homeostasis (NCBI Gene). In disease states, particularly cancer and fibrosis, these kinases are often overactivated, contributing to tumor progression, metastasis, and immune suppression (Yingling et al., 2017). Small-molecule inhibitors such as galunisertib (LY2157299) target these kinases to disrupt TGF-beta-mediated signaling, showing potential in treating advanced malignancies and fibrotic conditions (Tocris Bioscience). Understanding the collective inhibition of these related kinases is essential for evaluating the efficacy and safety profiles of multi-kinase inhibitors in clinical development (Yingling et al., 2017).

Other names

MINK, ALK6, ACVR2B and related kinasesMisshapen-like kinase 1Bone morphogenetic protein receptor type-1BActivin receptor type-2BALK6ACVR2BMINK1TGF-beta signaling pathway kinases

ATP-competitive inhibition of serine/threonine kinase activity, preventing the phosphorylation of downstream SMAD proteins and subsequent gene transcription.